🇺🇸 FDA
Patent

US 10239954

Antibodies specific for urokinase-type plasminogen activator and methods of use thereof for treating cancer

granted A61KA61K49/0032A61K49/0058

Quick answer

US patent 10239954 (Antibodies specific for urokinase-type plasminogen activator and methods of use thereof for treating cancer) held by The Regents of the University of California expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K49/0032, A61K49/0058, A61K51/1075